Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NOVA's CHAIRMAN AND CEO IS OUTGOING MERCK CHAIRMAN JOHN HUCK

Executive Summary

NOVA's CHAIRMAN AND CEO IS OUTGOING MERCK CHAIRMAN JOHN HUCK, who will assume the new position following completion of his tenure with Merck on June 30. Huck, 63, was named to the top spot of the Baltimorebased receptor technology company on April 29. He formally announced his intention to retire from Merck after 27 years with the company in Merck's 1985 annual report, released in February. At Nova, Huck will be teamed with another veteran research-based drug industry exec to direct the operations of the small research firm. Current Chairman, President and CEO Donald Stark joined Nova after a long career with Sterling. Stark will remain president of Nova. Nova's selection of Huck to head its operations is consistent with a trend among those biotech firms with products approaching the market, who fill top management slots with execs from research-based companies. Genentech's Kirk Raab, Cetus' Robert Fildes and Biogen's James Vincent have all worked for major pharmaceutical houses. Nova is currently collaborating with MIT scientists on a new polymer drug delivery system for the treatment of brain cancer.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel